References
- Kummar S, Ciesilski TE, Fogarasi MC. Management of small bowel adenocarcinoma. Oncology 2002; 16: 1364–9.
- Neugut Al, Marvin MR, ReIla VA, Chabot JA. An overview of adenocarcinoma of the small intestine. Oncology 1997; 11: 529–36.
- Dabaja BS, Suki D, Pro B, Bonnen M, Ajani J. Adenocarcinoma of the small bowel: presentation, prognostic factors and outcome of 217 patients. Cancer 2004; 101: 518–26.
- Solem CA, Harmsen WS, Zinsmeister AR, Loftus EV Jr. Small bowel adenocarcinoma in Crohn's disease: a case —con-trol study. Inflamm Bowel Dis 2004; 10: 32–5
- Bernstein D, Rogers A. Malignancy in Crohn's disease. Am J Gastroenterol. 1996; 9: 434–40.
- Abraham NA, Halverson A, Fazio VW, Rybicki LA, Goldblum JR. Adenocarcinoma of small bowel: a study of 37 cases with emphasis on histologic prognostic factors. Dis Colon Rectum 2002; 45: 1496-502.
- Ullman TA. Cancer in Inflammatory Bowel Disease. Curr Treat Options. Gastroenterol 2002; 5: 163–71.
- Korman MU. Radiological evaluation and staging of small intestine neoplasms. Eur J Radiol 2002; 42: 193–205.
- Sigel JE, Petras RE, Lashner BA, Fazio VW, Goldblum JR. Intestinal adenocarcinoma in Crohn's disease: a report of 30 cases with focus on coexisting dysplasia. Am J.Surg Pathol 1999; 23: 651–5.
- Jigyasu D, Bedikian AY, Stroehlein JR. Chemotherapy for primary adenocarcinoma of the small bowel. Cancer 1984; 53: 23–5.
- Crawley C, Ross P, Norman A, Hill A, Cunningham D. The Royal Marsden experience of a small bowel adenocarci-noma treated with protracted venous infusion 5 —fluorouracil.Br J Cancer 1998; 78: 504–10.
- Copson ER, Darby A, Harvey M, Geldart T, Iverson TJ. Epirubicin, cisplatin and infusional 5-fluorouracil chemotherapy for locally advanced and metastatic small bowel adenocarcinoma. Proc Am Soc Clin Oncol 2002: abstract 2347.
- Gibson MK, Holcroft CA, Kyols LK, Haller D. Phase II study of 5-fluorouracil, doxorubicin and mitomycin C for metastatic small bowel adenocarcinoma. Oncologist 2005; 10: 132–7.
- Polyzos A, Kouraklis G, Giannopoulos A, Bramis J, Delladetsima JK, Sfikakis PP. Irinotecan as salvage chemotherapy for advanced small bowel adenocarcinoma: a series of three patients. J Chemother 2003; 15: 503–6.
- Czaykowski.P, Hui D. Partial response to irinotecan as second line chemotherapy for small bowel adenocarcinoma (SBA): experience over a 10-year period at the BC cancer agency. 2004 ASCO Gastrointestinal Symposium; Abstract 109.
- Janat MM, Zhou GZ, Bruckner HW, Szajer L, Coopermann A, Kurbacher C. Drug interactions demonstrable in an ex vivo ATP assay system for gastrointestinal cancers. Am Assoc Cancer Res 1999; 40: 3459 abstract 2286.
- Bruckner HW, Bathini D, Zak D, DeGregorio P, Marino J, Zhou G. Drug interaction based laboratory designed combination chemotherapy for pancreatic cancer. International Congress on Anti-Cancer Treatment Proceedings 2003: 203.
- Bruckner HW, Bathini D, Zak D, DeGregroio P, Marino J, Zhou G. PSA and Prostate cancer, response to low dose intensity chemotherapy. International Congress on Anti-Cancer Treatment Proceedings 2003: 276.
- Kozuch P, Grossband ML, Barzdins A, et al. Irinotecan combined with gemcitabine, 5-florouracil, leucovorin and cis-platin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer. Oncologist 2001; 6: 488–95.
- Rocha Lima CM, Leong SS, Sherman CA, et al. Irinotecan and gemcitabine in patients with solid tumors: phase I trial. Oncology (Huntingt) 2002; 16: 19–24.
- Correale P, Messinese S, Caraglia M, et al. A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluo-rouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma. Br J Cancer 2004 4; 90 (9): 1710–4.
- Hagipantelli R, Saliba F, Misset JL. Pathophysiology and therapy of Irinotecan (CPT-11) induced delayed onset diarrhea: a prospective assessment. Proc Am Soc Clin Oncol 1995; 14: 464 abstract 1499.
- Rocha Lima CM, Eckardt JR, Leong SS, Sherman CA, Perkel JA, Putman T. Single agent gemcitabine and gemc-itabine/irinotecan combination (irinogem) in non small cell lung cancer. Semin Oncol 1999; 26: 43–50.
- Saliba F, Hagipantelli R, Misset JL, Bastian G, Vassal G, Bonnay M. Pathophysiology and therapy of irinotecan—induced delayed onset diarrhea in patients with advanced colorectal cancer: a prospective assessment. J Clin Oncol 1998; 16: 2745–51.
- Bruckner HW, Cohen CJ, Deppe G, et al. Chemotherapy of gynecological tumors with platinum. J Clin Hemato Oncol 1977; 7: 619–632.